APGE
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Apogee Therapeutics reported positive 52-week Phase 2 data for Zumilokibart showing sustained and improved responses in atopic dermatitisMar 23, 2026
- Apogee Therapeutics reports positive interim Phase 1b results for Zumilokibart (APG777), its potential best‑in‑class anti‑IL‑13 antibody, in mild‑to‑moderate asthma and outlines 2026 milestonesJan 6, 2026
- Apogee Therapeutics announces positive interim Phase 1 results from healthy volunteer trial of APG333, its novel half-life extended TSLP antibodyNov 10, 2025
- Apogee Therapeutics announces late-breaker presentation of 16-week data from Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis at upcoming EADV 2025 congressSep 11, 2025
- Apogee Therapeutics announces positive 16-week data from Phase 2 APEX trial of APG777, a potential best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitisJul 11, 2025